Topline Clinical Data Demonstrates Activity of SOR102 Across Multiple Clinical Endpoints Supporting Advancement to Phase 2 Development SALT LAKE CITY, UT, USA I 19, 2024 I Sorriso Pharmaceuticals, a ...
A new study may explain why some Crohn's disease patients still experience symptoms despite the absence of inflammation.
A study from University of Michigan researchers may provide an explanation for why some patients with Crohn's disease continue to experience symptoms, even in the absence of inflammation.
Dr. Axelrod was also recently appointed as a co-director for the Inflammatory Bowel Disease Center at NYU Langone. Steven Brant, MD. Rutgers University (New Brunswick, N.J.) Dr. Brant, a leader in ...
Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...
Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...
Patients with inflammatory bowel disease experience significant improvements in quality of life after using cannabis-based ...
Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could ...
Teva Pharmaceuticals' shares soared and Sanofi's stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease.
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback